8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


         Date of report (Date of earliest event reported): July 29, 2004


                         AMERICAN BIO MEDICA CORPORATION
- --------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

               New York                  0-28666               14-1702188
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of   (Commission File Number)    (IRS Employer
        Incorporation)                                    Identification Number)



              122 Smith Road, Kinderhook, NY                    12106
- --------------------------------------------------------------------------------
        (Address of Principal Executive Offices)              (Zip Code)




       Registrant's telephone number, including area code: (800) 227-1243





ITEM 5. OTHER MATTERS

      On July 29, 2004, the Registrant's Board of Directors appointed Carl A.
Florio to its Board of Directors.


ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.

         (c)  Exhibits.

              The following exhibits are filed with this report on Form 8-K:

99.1     American Bio Medica Corporation press release dated August 9, 2004.





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                AMERICAN BIO MEDICA CORPORATION
                                                (Registrant)


Dated:  August 9, 2004                          By: /s/ Keith E. Palmer
                                                    ----------------------------
                                                    Keith E. Palmer
                                                    Chief Financial Officer





                                  Exhibit Index


Exhibit No.             Description                                    Page No.
- -----------             -----------                                    --------

    99.1                Press Release dated August 9, 2004                5

EX-99

                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE:

             ABMC APPOINTS CARL A. FLORIO TO ITS BOARD OF DIRECTORS

KINDERHOOK, NY, August 9, 2004 - American Bio Medica Corporation (NASDAQ:ABMC)
announced today that Carl A. Florio, President and CEO of Hudson River Bank and
Trust Company, has been appointed to its Board of Directors. This appointment
brings the number of independent directors on ABMC's 6-person Board to 4,
continuing ABMC's commitment to maintaining a majority of independent directors.

"Carl's financial background along with his experience as an officer and
director of a public company makes him a valuable addition to the ABMC Board",
stated ABMC Founder and Director Stan Cipkowski. "ABMC has recognized the need
for a Board of Directors that is comprised of a majority of independent,
qualified individuals that will be committed to the Company and its
shareholders."

Mr. Florio has served as President and CEO of HRBT since 1996. From 1993 to 1996
Mr. Florio served as the Chief Financial Officer of HRBT. Prior to joining HRBT,
he was a partner at a regional accounting firm. He is currently a board member
of Hudson River Bancorp, Inc. (NASDAQ:HRBT), Hudson River Bank & Trust Company
Foundation, State University of New York at Albany Foundation, Fuller Road
Management, Columbia-Greene Community College Foundation, Columbia Children's
Center, WMHT, AAA Hudson Valley, Hudson Development Corp.and Community Bankers
Association of NYS.

For more information on ABMC or its drug testing products, please visit
www.abmc.com

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops
manufactures and markets accurate, cost-effective immunoassay diagnostic test
kits, including some of the world's most effective point of collection tests for
drugs of abuse. The Company and its worldwide distribution network target the
workplace, government, corrections, clinical and educational markets. ABMC's
Rapid Drug Screen(R), Rapid OneO, Rapid Tec(R) and RDS(R) InCup(TM) products
test for the presence or absence of drugs of abuse in urine, while OralStat(R)
tests for the presence or absence of drugs of abuse in oral fluids. ABMC has
been named among the 2002 Deloitte & Touche Technology Fast 500, a listing of
the fastest-growing technology companies in North America.

This release may contain forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results to
differ, and such differences could be material. Such risks and uncertainties
include, but are not limited to, the following: continued acceptance of the
Company's products, increased levels of competition in our industry, the
acceptance of new products, inherent risks associated with product development
and intellectual property rights, the Company's dependence on key personnel,
third party sales and suppliers. There can be no assurance that the Company will
be successful in addressing such risks and uncertainties and the Company assumes
no duty to update any forward-looking statements based upon actual results.
Investors are strongly encouraged to review the section entitled "Risk Factors"
in the Company's annual report on Form 10-KSB for the fiscal year ended December
31, 2003, and quarterly reports on Form 10-QSB on file with the Securities and
Exchange Commission for a discussion of risks and uncertainties that could
affect operating results and the market price of the Company's common shares.

                                      # # #